Passage Bio
CompanyUnited States
Passage Bio develops one asset, in phase 1 (PBFT02 in C9orf72). Mostly gene therapy acting on autophagy, proteostasis and inflammation; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 1
- 1
- Trial
- 0
- Signals
Pipeline
1AAV1 gene therapy delivering functional human progranulin
Phase 1, Gene therapy, Autophagy, Proteostasis, C9orf72, dementia frontotemporal
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials1
- Similar companies6